Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 14-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott Launches 14-valent Pneumococcal Vaccine for Children in India
Details : A pneumococcal conjugate vaccine PneumoShield 14 has been launched in India, for children from 6 weeks of age, offering broad protection than currently available vaccines for pneumococcal infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : 14-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Everolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries below the Knee
Details : The FDA approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System to keep arteries open, delivering Everolimus to support healing in patients with chronic limb-threatening ischemia.
Product Name : Esprit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : Everolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elecare
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott to Release Elecare® Amino Acid-Based Formulas to Help Meet Critical Patient Need
Details : EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas.
Product Name : Elecare
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Elecare
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbetocin Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The novel, room-temperature-stable (RTS), single-dose formulation of Carbetocin will address prevailing challenges with existing protocols that require cold-chain storage and transportation.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Carbetocin Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol,Dydrogesterone
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC
Details : Estradiol, also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles.
Product Name : Femoston
Product Type : Hormone
Upfront Cash : Inapplicable
July 15, 2021
Lead Product(s) : Estradiol,Dydrogesterone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India
Details : After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern r...
Product Name : Xigduo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2021
Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Everolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold
Details : This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (...
Product Name : Esprit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Everolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivabradine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients
Details : Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2020
Lead Product(s) : Ivabradine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable